ProKidney Corp. (NASDAQ:PROK) Insider Purchases $629,652.98 in Stock

ProKidney Corp. (NASDAQ:PROK - Get Free Report) insider Control Empresarial De Capital purchased 1,032,218 shares of the company's stock in a transaction that occurred on Thursday, April 10th. The shares were purchased at an average cost of $0.61 per share, with a total value of $629,652.98. Following the completion of the purchase, the insider now owns 72,592,325 shares of the company's stock, valued at $44,281,318.25. The trade was a 1.44 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Control Empresarial De Capital also recently made the following trade(s):

• On Wednesday, April 16th, Control Empresarial De Capital purchased 100,000 shares of ProKidney stock. The shares were acquired at an average cost of $0.75 per share, for a total transaction of $75,000.00.
• On Monday, April 14th, Control Empresarial De Capital bought 268,105 shares of ProKidney stock. The stock was acquired at an average price of $0.73 per share, for a total transaction of $195,716.65.

ProKidney Stock Down 0.6 %

NASDAQ PROK traded down $0.01 during trading hours on Friday, hitting $0.79. 1,018,709 shares of the company were exchanged, compared to its average volume of 684,013. The stock has a market cap of $231.49 million, a PE ratio of -1.44 and a beta of 1.52. ProKidney Corp. has a 52 week low of $0.46 and a 52 week high of $4.44. The stock has a 50-day moving average price of $1.02 and a 200 day moving average price of $1.50.

ProKidney (NASDAQ:PROK - Get Free Report) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The business had revenue of $0.08 million for the quarter. As a group, sell-side analysts anticipate that ProKidney Corp. will post -0.57 earnings per share for the current year.

Institutional Trading of ProKidney

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PROK. Charles Schwab Investment Management Inc. raised its holdings in shares of ProKidney by 150.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 749,718 shares of the company's stock worth $1,439,000 after buying an additional 450,548 shares during the period. The Manufacturers Life Insurance Company increased its stake in ProKidney by 54.6% in the third quarter. The Manufacturers Life Insurance Company now owns 37,981 shares of the company's stock worth $73,000 after purchasing an additional 13,415 shares during the period. State Street Corp lifted its position in shares of ProKidney by 16.2% during the third quarter. State Street Corp now owns 1,428,318 shares of the company's stock worth $2,742,000 after purchasing an additional 198,836 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of ProKidney during the third quarter valued at $41,000. Finally, Barclays PLC grew its holdings in shares of ProKidney by 575.7% in the third quarter. Barclays PLC now owns 146,321 shares of the company's stock worth $281,000 after purchasing an additional 124,667 shares during the last quarter. 51.59% of the stock is owned by hedge funds and other institutional investors.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.